Cirio advises Intervacc in connection with Exclusive Distribution Agreement
Intervacc AB (publ) has entered into an exclusive distribution agreement with Dechra Pharmaceuticals PLC to commercialize Intervacc’s leading vaccine candidate Strangvac® in Europe, excluding the Nordic and Baltic countries. Strangvac® is in late-stage regulatory review with the European Medicines Agency and is an innovative vaccine against equine strangles, a highly contagious infectious disease that affects horses globally. The distribution agreement is based on a transfer price plus additional future payments linked to pre-defined sales milestones.
Cirio's team consisted of Senior counsel Anders Burén, partner Ulrica Salomon and associate Anna Hovstadius.
